The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy

Vimal Krishnan, Guila Delouya, Jean-Paul Bahary, Sandra Larrivée, Daniel Taussky
  • BJU International, March 2014, Wiley
  • DOI: 10.1111/bju.12587
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Daniel Taussky

In partnership with: